MedPacto, Inc.

ACTIVE

Borim Bldg., Seoul, 首尔特别市, South Koreawww.medpacto.comPublic63 employeesEstablished: 2013-06-19

Clinical Trials

0 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2013

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

70.0%

Phase 2

30.0%

Trial Status Distribution

Completed

60.0%

Recruiting

10.0%

Terminated

10.0%

Withdrawn

20.0%

Clinical Trials

Trials sponsored by this organization (10)

Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma

Phase 1

Recruiting

interventional

May 202348 participants

Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)

Phase 2

Withdrawn

interventional

Jun 202176 participants

Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects

Phase 2

Terminated

interventional

Dec 202011 participants

Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

Phase 2

Withdrawn

interventional

Dec 201948 participants

Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC

Phase 1

Completed

interventional

Feb 201960 participants

Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer

Phase 1

Completed

interventional

Dec 2018120 participants

TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer

Phase 1

Completed

interventional

Aug 201862 participants

Effect of Food on the Pharmacokinetics of TEW-7197 in Healthy Subjects

Phase 1

Completed

interventional

Aug 201816 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations